Pulse Biosciences (NASDAQ:PLSE) Lifted to Sell at StockNews.com

Pulse Biosciences (NASDAQ:PLSEGet Rating) was upgraded by stock analysts at StockNews.com to a “sell” rating in a report issued on Thursday.

A number of other research analysts have also weighed in on the stock. Stephens lowered shares of Pulse Biosciences from an “overweight” rating to an “equal weight” rating in a research note on Thursday, May 12th. HC Wainwright lowered shares of Pulse Biosciences from a “buy” rating to a “neutral” rating in a research report on Friday, May 13th.

Pulse Biosciences Stock Performance

Shares of NASDAQ PLSE opened at $1.59 on Thursday. The firm has a 50 day moving average price of $1.88 and a 200 day moving average price of $4.03. Pulse Biosciences has a 52-week low of $1.41 and a 52-week high of $29.16.

Pulse Biosciences (NASDAQ:PLSEGet Rating) last issued its quarterly earnings data on Wednesday, May 11th. The company reported ($0.54) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.58) by $0.04. The firm had revenue of $0.44 million for the quarter, compared to analyst estimates of $0.70 million. On average, sell-side analysts forecast that Pulse Biosciences will post -1.66 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of PLSE. Westside Investment Management Inc. lifted its stake in Pulse Biosciences by 41.4% in the 2nd quarter. Westside Investment Management Inc. now owns 178,195 shares of the company’s stock valued at $272,000 after purchasing an additional 52,166 shares during the last quarter. Bank of America Corp DE grew its holdings in Pulse Biosciences by 5.1% during the first quarter. Bank of America Corp DE now owns 820,390 shares of the company’s stock worth $3,988,000 after purchasing an additional 39,645 shares during the period. Renaissance Technologies LLC bought a new position in Pulse Biosciences during the first quarter worth about $378,000. Advisor Group Holdings Inc. grew its holdings in Pulse Biosciences by 25.5% during the first quarter. Advisor Group Holdings Inc. now owns 25,878 shares of the company’s stock worth $126,000 after purchasing an additional 5,265 shares during the period. Finally, GSA Capital Partners LLP bought a new position in Pulse Biosciences during the fourth quarter worth about $164,000. Institutional investors own 13.63% of the company’s stock.

Pulse Biosciences Company Profile

(Get Rating)

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. It offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.

Recommended Stories

Receive News & Ratings for Pulse Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulse Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.